Allarity Therapeuticsview News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CAMBRIDGE, MA / ACCESSWIRE / April 17, 2023 / Allarity Therapeutics (NASDAQ:ALLR) dosed its first patient in Phase 1b of its clinical trial for the novel combination therapy of two drugs, stenoparib and

United kingdomMansoor raza mirzaKathleenn mooreAllarity therapeuticsviewThomas pedersenThomas jensenClinical researchDepartment of oncology at copenhagen university hospitalStephenson cancer centerSalarius pharmaceuticalsUniversity of oklahoma college medicineNational cancer instituteAllarity therapeutics incAllarity therapeuticsCopenhagen university hospitalScientific advisory board